logo-loader
HealthMedical technology & services
viewArix Bioscience PLC

Arix Biosciences' progress significantly undervalued, suggests US broker

Arix’s portfolio companies are involved in 15 clinical trials

fag ends
COPD is a life threatening disease

A significant disconnect has opened between the value of Arix Bioscience PLC’s portfolio companies (LON:ARIX) and its share price, according to HC Wainwright.

The company's investments have delivered strong increases in underlying net asset value, but this has not translated over to the share price, says the US broker.

WATCH:Arix Bioscience seeing 'tremendous flow of opportunity' for further investments

Shares are currently trading below the initial IPO price when the company only had five group business investments, now it has 13.

Newsflow over the next 18 months should help correct this, suggests the broker.

Arix’s portfolio companies are involved in 15 clinical trials with data expected from ten, including Phase III studies.

Twelve other clinical programmes are scheduled to start during the period.

On that note, the broker highlights AIM-listed Verona Pharma PLC’s (LON:VRP) announcement yesterday about a new study of its RPL554 treatment.

Arix has a 2.5% stake in Verona, which will carry out a Phase II trial to asses the drug as an add-on treatment to help the breathing in moderate to severe COPD.

The trial data will also frame a Phase III triple therapy trial for RPL554 as a bronchodilator for COPD sufferers.

“Overall, we reiterate our initial view that Arix provides investors with a publicly traded vehicle to take part in venture capital initiatives and potential benefits,” said Wainwright.

Key to this is the experience of Arix’s management, which includes: academic life science research; creation of life science start-up companies; venture capital; and management positions in large pharmaceutical companies.

Wainwright has a 'buy' rating and a 314p price target.

Arix shares today were trading at 173.5p.

 

Quick facts: Arix Bioscience PLC

Price: 119.9 GBX

LSE:ARIX
Market: LSE
Market Cap: £159.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience 'building a very exciting, diversified healthcare company'

Dr Joe Anderson, chief executive of Arix Bioscience Plc (LON:ARIX) runs Proactive Investors through the company's strategy and outlook. ''We're focused on the innovation end of healthcare, which is exactly where we believe the value is in healthcare today'', Anderson says.

on 19/5/17

2 min read